1. Home
  2. PDLB vs CLLS Comparison

PDLB vs CLLS Comparison

Compare PDLB & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ponce Financial Group Inc.

PDLB

Ponce Financial Group Inc.

HOLD

Current Price

$17.51

Market Cap

401.0M

Sector

N/A

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$4.27

Market Cap

384.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDLB
CLLS
Founded
1960
1999
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
401.0M
384.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
PDLB
CLLS
Price
$17.51
$4.27
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.33
AVG Volume (30 Days)
50.9K
36.3K
Earning Date
04-24-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
160.87
N/A
EPS
1.20
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.62
P/E Ratio
$14.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.88
$1.33
52 Week High
$18.01
$5.48

Technical Indicators

Market Signals
Indicator
PDLB
CLLS
Relative Strength Index (RSI) 63.33 65.40
Support Level $15.84 $3.25
Resistance Level $18.01 $4.46
Average True Range (ATR) 0.37 0.22
MACD 0.05 0.12
Stochastic Oscillator 72.22 79.09

Price Performance

Historical Comparison
PDLB
CLLS

About PDLB Ponce Financial Group Inc.

Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: